Calibrate vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health company delivering one-year GLP-1 programs with semaglutide or tirzepatide plus behavioral coaching, nutrition, and activity guidance via physician-supervised telehealth.
About
Calibrate is a metabolic health company that delivers a one-year weight loss program combining GLP-1 receptor agonist medications — including semaglutide and tirzepatide — with behavioral coaching, food education, sleep guidance, and activity programming through a telehealth platform. The program's clinical foundation differentiates it from consumer weight loss apps and traditional diet programs by centering medication management under physician supervision as the primary intervention, with lifestyle coaching structured to support long-term habit change alongside pharmaceutical treatment. Calibrate's approach reflects the clinical consensus that obesity is a chronic metabolic disease requiring medical treatment rather than a lifestyle choice addressable through willpower alone.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.